Needle-Phobia Fails To Carry The Day: NICE Rejects Orencia For Second-Line Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K.'s cost watchdog, the National Institute for Health and Clinical Excellence, has rejected Bristol's Orencia as a second-line therapy for rheumatoid arthritis in draft guidance, although it has changed its mind on use of the drug before.